Display options
Cite
Kaiser CA, Cozzio A, Hofbauer GF, et al. Disfiguring annular sarcoidosis improved by adalimumab. Case Rep Dermatol. 2011;3(2):103-6doi: 10.1159/000328796.
Kaiser, C. A., Cozzio, A., Hofbauer, G. F., Kamarashev, J., French, L. E., & Navarini, A. A. (2011). Disfiguring annular sarcoidosis improved by adalimumab. Case reports in dermatology, 3(2), 103-6. https://doi.org/10.1159/000328796
Kaiser, C A, et al. "Disfiguring annular sarcoidosis improved by adalimumab." Case reports in dermatology vol. 3,2 (2011): 103-6. doi: https://doi.org/10.1159/000328796
Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA. Disfiguring annular sarcoidosis improved by adalimumab. Case Rep Dermatol. 2011 May;3(2):103-6. doi: 10.1159/000328796. Epub 2011 May 17. PMID: 21677887; PMCID: PMC3104865.
Copy Download .nbib Format: NLM
Share it on

Case Rep Dermatol. 2011 May;3(2):103-6. doi: 10.1159/000328796. Epub 2011 May 17.

Disfiguring annular sarcoidosis improved by adalimumab.

Case reports in dermatology

C A Kaiser, A Cozzio, G F L Hofbauer, J Kamarashev, L E French, A A Navarini

Affiliations

  1. Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

PMID: 21677887 PMCID: PMC3104865 DOI: 10.1159/000328796

Abstract

Depending on the location, dermatoses can produce blemishes that severely impair quality of life and require highly effective treatment that is otherwise used for extensive skin involvement. We report the case of a 39-year-old, otherwise healthy male disfigured by an 8 × 7-cm hypopigmented and centrally atrophic annular plaque with erythematous indurated borders in an area of scar tissue on his forehead. Skin biopsies revealed non-caseating granulomas, and hilar involvement was identified, leading to the diagnosis of systemic sarcoidosis stage II with cutaneous involvement. The lesions proved resistant to multiple therapies, but responded within 4 months to adalimumab with regression of the lesion and inflammatory infiltrate. The visual analogue scale of disease activity decreased from 7/10 to 3.5/10, and the Dermatology Life Quality Index from 16/30 to 3/30 points. In conclusion, TNF-α inhibition can control inflammation and disfigurement by cutaneous sarcoidosis and restore quality of life.

Keywords: Adalimumab; Cutaneous sarcoidosis; Sarcoidosis treatment; Systemic sarcoidosis; TNF-α antagonist

References

  1. Arch Bronconeumol. 2011 Apr;47(4):208-12 - PubMed
  2. Arch Dermatol. 2005 Jul;141(7):910-1 - PubMed
  3. J Rheumatol. 2007 Feb;34(2):380-5 - PubMed
  4. Nature. 1992 Apr 16;356(6370):604-7 - PubMed
  5. Expert Opin Ther Targets. 2010 Jan;14(1):21-9 - PubMed

Publication Types